The online version of this article (doi:10.1186/s12890-015-0109-9) contains supplementary material, which is available to authorized users.
All authors declare they have no competing interests.
JBG participated in design of the study, collated clinical data, and drafted the manuscript. DWR participated in the design of the study and edited the manuscript. BJC participated in design of the study, provided clinical data on study subjects, and edited the final manuscript. SCB conceived the study, participated in design of the study, and edited the final manuscript. The Melioid CF Group provided clinical data on study subjects and edited the final manuscript. All authors read and approved the final manuscript.
Several cases of Burkholderia pseudomallei infection in CF have been previously reported. We aimed to identify all cases globally, risk factors for acquisition, clinical consequences, and optimal treatment strategies.
We performed a literature search to identify all published cases of B. pseudomallei infection in CF. In addition we hand-searched respiratory journals, and contacted experts in infectious diseases and CF around the world. Supervising clinicians for identified cases were contacted and contemporaneous clinical data was requested.
25 culture-confirmed cases were identified. The median age at acquisition was 21 years, mean FEV1 % predicted was 60 %, and mean BMI was 19.5 kg/m2. The location of acquisition was northern Australia or south-east Asia for most. 19 patients (76 %) developed chronic infection, which was usually associated with clinical decline. Successful eradication strategies included a minimum of two weeks of intravenous ceftazidime, followed by a consolidation phase with trimethoprim/sulfamethoxazole, and this resulted in a higher chance of success when instituted early. Three cases of lung transplantation have been recorded in the setting of chronic B. pseudomallei infection.
Chronic carriage of B. pseudomallei in patients with CF appears common after infection, in contrast to the non-CF population. This is often associated with an accelerated clinical decline. Lung transplantation has been performed in select cases of chronic B. pseudomallei infection.
Price EP, Sarovich DS, Mayo M, Tuanyok A, Drees KP, Kaestli M et al. Within-host evolution of Burkholderia pseudomallei over a twelve-year chronic carriage infection. MBio. 2013;4(4). doi: 10.1128/mBio.00388-13.
Radhakrishna N, Morton J. Burkholderia pseudomallei in cystic fibrosis and treatment complications. Respirol Case Rep. 2014. doi: 10.1002/rcr2.86.
Lezana JL, Novoa O, Lezana MA. Epidemiology of Pseudomonas in Mexican CF patients [abstract]. Pediatric Pulmonolgy. 1989;4(Supplement):138.
Melioidosis. Centre for Disease Control, Darwin. 2012. http://health.nt.gov.au/library/scripts/objectifyMedia.aspx?file=pdf/43/46.pdf&siteID=1&str_title=Melioidosis.pdf. Accessed December 2 2014 2104.
- An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis
James B. Geake
David W. Reid
Bart J. Currie
Scott C. Bell
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II